Introduction
Schizophrenia is a severe psychiatric disorder with a lifetime prevalence of 1% and a high heritability (estimated at up to 80%). 1 Despite the availability of a wide range of different antipsychotic drugs and optimized therapeutic strategies, one-fifth to one-third of people with schizophrenia are considered to have a treatment-resistant illness. [2] [3] [4] These patients have persistent psychotic symptoms and poor functioning despite adequate treatment with conventional or novel antipsychotic drugs. 2 Clozapine has been shown to be the treatment of choice [5] [6] [7] in patients with few neurological adverse events and to have a beneficial effect in terms of mental state and suicide mortality. 8 It is estimated, however, that approximately 30% of patients treated with clozapine do not respond adequately, remaining with persistent psychotic symptomatology despite having received adequate treatment for sufficient periods. These latter patients, who do not respond to clozapine either, are considered to have 'super-refractory' or ultra-resistant schizophrenia (URS). [9] [10] [11] In contrast with patients who at least partially respond to antipsychotic medications (including those who respond to clozapine), patients with URS continue to experience moderate-to-severe persistent positive psychotic symptoms and no social and/or occupational remission in spite of treatment with clozapine and at least two periods of treatment with conventional or atypical antipsychotic drugs. Such patients represent a challenge for understanding the mechanisms behind schizophrenia and the response to antipsychotic drugs as well as a major social and economic burden. 9 After reviewing the literature, we have proposed operational clinical and biological criteria derived from Kane's definition of treatment-resistant schizophrenia and standards defining eligibility to clozapine augmentation strategies. 5, 10 In an attempt to improve therapeutic response by personalizing antipsychotic treatment, pharmacogenetics aims to identify the underlying mechanisms of treatment resistance. 12 So far, pharmacogenetic studies of antipsychotic responses have focussed either on pharmacodynamics, assessing the candidate genes that encode major neurotransmitter receptors, or on pharmacokinetics, exploring genetic variants of the cytochrome enzymes and/or their regulators. However, genes encoding proteins that contribute to neurogenesis, neurite formation and neuronal plasticity may affect not only the pathophysiology of schizophrenia, but also response or resistance to antipsychotics. [13] [14] [15] [16] [17] The gene encoding Disrupted in Schizophrenia 1 (DISC1) is a moderately conserved gene that codes for a 93.6-kDa protein of 854 amino acids with a globular N-terminus domain, a coiled C-terminus domain and several other functional domains. 18 The role of DISC1 is largely unknown, but these identified domains allow the DISC1 protein to interact with centrosomal and cytoskeletal proteins (NUDEL), neurodevelopmental regulators (NDE1/NDEL1 and FEZ1), neurosignalling regulators (PDE4B and PDE4D) and membrane-associated and signal transduction proteins such as activating transcription factor (ATF)4 and ATF5. 19, 20 Depletion of DISC1 or expression of a truncated protein impairs neurite outgrowth and proper development of the cerebral cortex. 21, 22 Moreover, as recently shown, DISC1 regulates neuronal proliferation during development and even later, in brain areas in which neurogenesis still occurs (dentate gyrus, olfatory bulb). This effect on neurogenesis is achieved through activation of the glycogen synthase kinase 3b/b catenine pathway. 23 DISC1 has also been implicated in animal behaviour. 24 Adult mice, in which the expression of DISC1 is blocked even transiently during fetal life, show alteration in the brain dopaminergic system and behaviours resembling those encountered in patients with schizophrenia or depression. 25 Interestingly, these behaviours are improved after treating rodents with compounds that re-establish the DISC1 signalling pathway. 23 Consequently, DISC1 is a promising target for the development of novel treatment strategies for schizophrenia and depression.
DISC1 was originally identified as a susceptibility gene for schizophrenia in a Scottish family with a balanced chromosomal translocation (1q42.1:11q14.3) that co-segregates with major mental illnesses, including schizophrenia, bipolar disorder and major depression. 26 Subsequent association studies using different samples provided evidence of an association between DISC1 and schizophrenia as well as with many behavioural, cognitive 27, 28 and structural endophenotypes 27, 29 of this disorder, and with other major psychiatric illnesses such as autism and bipolar disorder. 20 Three relatively common missense variants, belonging to distinct haplotypes, have been variably associated with the risk of schizophrenia: rs3738401, rs6675281 and rs821616. These variants result in a substitution of amino acids, respectively, of Gln by Arg, Leu by Phe and Ser by Cys in positions 264, 607 and 704 of the protein (Q264R, L607F, and S704C). The rs3738401 polymorphism, located in the second exon, forms with another polymorphism (rs751299) a two single-nucleotide polymorphism (SNP) haplotype:T-A overtransmitted to males with psychotic disorder. 30 The rs3738401 variant also significantly alters the expression level of CHRNA5, which encodes the a5 nicotinic acetylcholine receptors, TUBB3 and TUBD1, encoding a3 tubulin and d1 tubulin, respectively. These proteins are potential targets for psychotropic drugs (Ingenuity Systems, www. ingenuity.com). 31 The rs6675281 variant, carried by the haplotype block Hep 1 in exon 9, has been shown to be over-represented in individuals with schizo-affective disorder. 32 It is located in a mutiple-binding domain and thus affects DISC1 interactions with numerous proteins such as NUDEL, MAP1A, ATF4 and ATF5. 31 The rs821616 variant, or haplotype containing it, has also been associated with the risk of schizophrenia and with structural and functional alterations in the hippocampal formation. 29 In addition, it has been speculated that rs821616 has pathophysiological implications, as this missense variant has also been shown to alter binding of NDEL1 31 . We hypothesized that the above genotypic variants and their potential functional consequences contribute to the pathophysiological mechanisms of antipsychotic ultraresistance. For this purpose, we examined their association, in a sample of Caucasian patients, phenotyped with respect to treatment response to antipsychotics as patients suffering from either URS or treatment-responding schizophrenia (RS). The characterization of treatment response is based on operational clinical and biological criteria defined in a former paper. 10 
Materials and methods

Population
All participants, after receiving a full description of the study, gave their informed, written consent. All study procedures were approved by the French ethics committees and were in accordance with the Helsinki declaration.
We The patients fulfilled the DSM IV (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition) criteria for schizophrenia as determined by a structured interview, the Diagnosis Interview for Genetic Studies (DIGS version 3.0), 33 conducted by trained psychiatrists and psychologists who reached a consensual diagnosis based on direct interview, information from practitioners and family and prospectively documented clinical case reports. Psychopathological assessments included the expanded version of the Brief Psychiatric Rating Scale (BPRS-E(A)), [34] [35] [36] the CGI-S (Clinical Global Impression-Severity Scale), 37 GAF (Global Assessment of Functioning Scale) 38 and the PANSS (Positive and Negative Syndrome Scale). 39 Healthy control subjects were recruited through local advertisements. They were screened using DIGS 3.0 before inclusion in the study according to the following criteria: Caucasian descent, no family history of schizophrenia, alcoholism or bipolar disorder in both first-and seconddegree relatives and no past or present personal history of any DSM-IV axis 1 mental disorder.
Treatment response phenotype characterization
The characterization of treatment response phenotype was carried out retrospectively. Each clinical and therapeutic history was reviewed by a trained psychiatrist (FM). Patients were withdrawn from the phenotypic characterization process when data were unavailable or insufficient. Former or current substance abuse and/or dependence on any kind of psychoactive substance, but not nicotine, as well as comorbid general medical conditions influencing response to antipsychotic drugs were also exclusion criteria.
Stringent criteria for treatment response, derived both from Kane's definition of resistant schizophrenia 5 and standards defining eligibility to clozapine augmentation strategies, 10 were applied to information collected from medical files, interviews with patients, families and treating psychiatrists. As the criteria from the literature for response to treatment refer to the 18-item BPRS, we extracted the value of the 18 items 40 from the expanded 24-item form. This French validated version allows the 1-7 rating and includes a semistructured interview with anchor points that increases its reliability. 36 Patients with URS were defined as patients who continue to experience persistent positive psychotic symptoms: item score of X4 (moderate) on at least two of four positive symptoms on the BPRS (grandiosity, suspiciousness, hallucinations and unusual thoughts), 40 current presence of at least moderately severe illness on the total BPRS-18 X45 and a score of X4 (moderate) on the CGI-S 37 despite (1) a period of clozapine therapy of at least 6 weeks, with a plasma concentration of X350 ng ml -1 and (2) at least two unsuccessful previous treatment trials with conventional or atypical antipsychotic drugs from two distinct families at a dose X600 mg of chlorpromazine equivalents. In addition, URS patients had not had a stable period of good social and/ or occupational functioning within the past 5 years (inability to maintain work and relationships) and had a current score on the GAF Scale 38 of p40. Although the response to electroconvulsivotherapy is not included in our criteria, we noted that 15 of the URS patients underwent electroconvulsivotherapy in combination with antipsychotic drugs and none remitted under this treatment.
The antipsychotic RS group consisted of patients who had experienced a partial or full remission within 6-8 weeks of continuous treatment with an atypical or a conventional antipsychotic drug (including clozapine). All patients who had received more than one antipsychotic and responded to treatment at least once were considered to be responders. Remission criteria were total 18-item BPRS score 40 of p30 with no more than one item scoring 4, a CGI 37 score of o3 (borderline mentally ill) and a GAF 38 score of X61. While classifying our patients, a third group of treatmentresistant illness patients were identified who had received at least two unsuccessful treatment periods with conventional or atypical antipsychotic drugs from two distinct families at a dose of X600 mg of chlorpromazine equivalents and were eligible for treatment by clozapine but who either had not received clozapine or received it for an insufficient length of time and/or at low doses. As we could not know whether these patients would respond to clozapine or not, and to avoid misclassification, this latter group was excluded from the second phase of the study.
Genotyping DNA was extracted from the blood by precipitation using Genisol Maxi-Prep Kit (ABgene, Epsom, UK). The three SNPs (Genome Build 36.3: rs3738401; position: 229896918, exon 2, rs6675281; position: 230020724, exon 9 and rs821616; position 230211221, exon 11) belong to separate haplotypes. Genotypes were determined using a predesigned TaqMan SNP genotyping assay (Applied Biosystems, Foster City, CA, USA). The TaqMan reaction was performed in a final volume of 10 íl consisting of 10 ng genomic DNA and TaqMan Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems) on an ABI PRISM 7000 Sequence Detection System (Applied Biosystems).
Statistical analysis
The Pearson's w 2 test, Student's t-test and Mann-Whitney Utest were used, where appropriate, to analyse clinical and demographical data. For differences between actual and expected frequencies of the three SNPs in the control group, we used the Hardy-Weinberg equilibrium equation. The frequencies of alleles were also compared between patients and controls and URS patients and RS patients using Pearson's w 2 analysis. A nominal probability (P-value) of o0.05 was considered statistically significant. To correct P-values for multiple comparisons and minimize type I risk error, both Bonferroni and permutation (with 10 000 permutations) tests were implemented. Analyses were performed using PLINK 1.06 software (http://pngu.mgh. harvard.edu/~purcell/plink/contact.shtml#cite). 41 
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Results
Comparison of patients with schizophrenia vs controls
In this case-control study, a total of 373 unrelated individuals including 222 patients (153 males and 69 females) and 151 healthy controls (64 males and 87 females) were recruited (Table 1) .
Of the three SNPs genotyped in the control sample, rs821616 deviated from the frequency expected under Hardy-Weinberg equilibrium (P ¼ 0.005). Compared with controls, the distribution of genotypes in patients with schizophrenia resulted in a significant difference with regard to rs821616 (P ¼ 0.031) but not rs3738401 or rs6675281. No significant differences were found when allelic repartition was studied between cases and controls, even when cases and controls were stratified according to gender.
Comparison of patients with URS vs RS
Among the 222 patients, 40 were characterized as URS (25 men (62.5%) and 15 women (37.5%)), and 99 patients were considered as RS (66 men (66.7%) and 33 women (33.3%)). The remaining patients were either treatment-resistant illness patients, for whom we could not assess the response to clozapine (n ¼ 33), or patients with insufficient data, toxic dependence and/or abuse and somatic comorbidity hindering drug response characterization (n ¼ 50).
There were no differences between URS and RS patients in the distribution of age, gender and age at first antipsychotic treatment (Table 1) . Significantly higher mean scores were observed in the URS group on the 24-item BPRS, the 18-item BPRS, the PANSS, on the positive subscale of the 18-item BPRS and on the CGI-S, reflecting the persistent symptoms present in resistant patients. The mean GAF score was significantly lower in the URS group (see Table 1 ).
The minor allele A of rs3738401 was significantly more frequent in URS than RS patients (P ¼ 0.012, Table 2 ). This remained significant after both Bonferroni correction (P ¼ 0.03) and permutation test (P ¼ 0.008). The A-containing genotypes (AA þ AG) were present in 85% in URS vs 50.5% in RS (Po0.001). Furthermore, the minor allele was over-represented in males with URS (P ¼ 0.012), suggesting a gender effect.
For rs6675281, the minor allele T was significantly associated with the RS group (Po0.022). The comparisons of genotypic and allelic repartition of rs821616 between URS and RS did not show any significant differences.
Discussion
In this study, we examine whether three previously described common DISC1 missense variants have a role in the pathophysiology of schizophrenia and in the mechanisms of resistance to antipsychotics. In addition to an association of rs821616 with schizophrenia, we find an original association of rs3738401 with ultra-resistance to antipsychotics.
Although a retrospective approach such as ours is not ideal, it provided us with the necessary insight for the definition of URS according to stringent criteria. The accuracy of information regarding therapeutic history collected from the prospectively documented medical files, available for all patients, as well as interviews with their families and their referent psychiatrists, allowed us to reduce potential biases.
The rs821616 SNP in DISC1 has already been reported to be associated with schizophrenia. 29, 42, 43 In our sample, nevertheless, the positive association should be considered with caution given the SNP genotype deviation from the 74.9 ± 9.9 o0.001
Abbreviations: 18-item BPRS, Brief Psychiatric Rating Scale 18 items with anchor points and 1-7 scaling system; 24-item BPRS, BPRS extended to 24 items with anchor points; AP, antipsychotic; CGI-S, Clinical Global Impressions Severity Scale; GAF, Global Assessment of Functioning Scale; NS, nonsignificant; Pos Subscale Score, BPRS Positive Symptom subscale scores; RS, responding schizophrenia; URS, ultra-resistant schizophrenia.
a Psychopathological scores established retrospectively at remitting point for RS and after a well-conducted period of treatment with clozapine for URS.
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Hardy-Weinberg equilibrium. There were no significant associations between schizophrenia and the two other tested polymorphisms, rs6675281 and rs3738401. The lack of association of rs6675281and schizophrenia is in line with the literature. 29, 43, 44 The rs3738401 SNP, together with rs751229, forms a common DISC1 haplotype, HEP3, spanning 62 kb from intron 1 to exon 2. HEP3 (T-A) was found to be overtransmitted to males with schizophrenia spectrum psychosis and severe mood disorders. 45 This result has been replicated independently for bipolar spectrum disorders and further strengthened by the finding of an association between HEP3 and rate of perseverative errors in the California Verbal Learning Test, a cognitive endophenotype for schizophrenia. 46 An extended region including HEP3 and two additional SNPs (rs1615409 and rs766288) was found to be over-represented in a sample of Finnish twins suffering from schizophrenia and also associated with impaired spatial working memory, increased reaction time to visual targets and reduced prefrontal grey matter. 27 Another study, in a North American sample, found an association between schizo-affective disorder and an under-transmitted haplotype carrying the A allele of rs3738401. Although not uniformly replicated, 47, 48 the evidence from the literature strongly suggests that the missense variant rs3738401 is involved in the pathophysiology of schizophrenia. The limited size of our sample could account for our failure to replicate this result with the whole group of patients with schizophrenia in comparison with healthy controls. On the other hand, the previously reported association could also be due to a sub-sample of patients with resistant schizophrenia.
Our main objective was to analyse genetic factors associated with URS. URS could help to decipher the underpinnings of schizophrenia as well as of the response to antipsychotic drugs. Clozapine is considered to be the treatment of last resort in schizophrenia and beyond this step, clozapine augmentation trials have not clearly shown beneficial effects. [49] [50] [51] Thus, to select a relatively homogenous subgroup of subjects, we decided to define treatment resistance on the basis of the response to clozapine and not on the usual criteria for treatment resistance (that is, eligibility for clozapine). Indeed, among the treatmentresistant patients, some will significantly respond to clozapine (approximately 30%) whereas the remainder will not, introducing a heterogeneity in the group regarding response to overall antipsychotic treatment.
We compared patients with URS with patients who at least partially respond to treatment and found significant associations: (1) the minor allele A of rs3738401 and A-containing genotypes were significantly more frequent in URS than RS patients and (2) the T allele of rs6675281 was over-represented in RS group. This latter allele has been previously reported to be overtransmitted in patients suffering from schizoaffective disorder. 32 Schizoaffective disorder combines psychotic and affective symptoms and, in general, has a better outcome and response to antipsychotics than schizophrenia. 45 It is possible that the rs6675281 variant contributes to the expression of a phenotype with a more prominent affective dimension that confers a better prognosis. 45 Finally, there was no association between rs821616 and URS. We cannot, nevertheless, preclude a role of this polymorphism in treatment response given its reported involvement in structural and functional brain alterations, 29, 52 as well as its suggested relevance to the effect of antipsychotics on brain morphology. 52 Overall, our results suggest a potential role of DISC1 variants, and especially of the rs3738401 polymorphism in a subset of patients suffering from URS. As mentioned above, rs3738401 is included in the haplotype HEP3, previously associated with cognitive dimensions in schizophrenia. 27, 28, 46 Despite the statistical association, it is difficult to eliminate the possibility that the global severity of the disease or other pathological dimensions, such as cognitive dysfunction, is in fact the mediating factor in this relationship. Complementary studies comparing response to antipsychotic medication with the severity of the disease or cognitive impairments along with genetic molecular investigations may help untangle this issue.
On the other hand, there is some evidence that DISC1 variants, and especially the rs3738401 polymorphism, have a functional influence on response to treatment. Clapcote et al. 53 showed that a missense-induced mutation in mice gives rise to a schizophrenia-related phenotype with a modified response to clozapine. Other more supportive arguments for a potential role of rs3738401 in drug response comes from the mining of publicly available expression data derived from lymphoblastoid cell lines of HapMap individuals showing significant alterations in genome-wide 31 In this study, the rs3738401 variant was shown to significantly alter the expression level of the TUBB3 and TUBD1 genes. 31 b-III-Tubulin, the product of TUBB3, is considered to be a neuronally specific tubulin that actively participates in neuronal structural rearrangements. 54 Thus, a deficit in b-III-tubulin expression could hinder antipsychotic-induced structural brain changes 55 and, consequently, interfere with their therapeutic effects. In fact, the potential healing properties of the products of TUBB3 and TUBD1 are being investigated. These proteins are being targeted by AL-108, a microtubule stabilizer and neuroprotectant peptide currently undergoing phase II trials for cognitive impairment in Alzheimer disease and schizophrenia. 56 Several limitations should be discussed. Although statistical significance persisted after adequate corrections for mutiple testings, the interpretation of our results should be weighted on the basis of the small sample size and, despite the stringent criteria, the bias introduced by possible misclassification. The small size of the sample also does not allow us to draw any definite conclusion on the gender effect observed in the association with rs3738401. In addition, we were not able to classify a substantial part of the initial group of patients either because of the presence of factors hindering drug response characterization (for example, substance abuse), insufficient information or because response to clozapine could not be inferred in treatmentresistant patients. Nevertheless, we compared the genotypic or allelic distributions for the three variants and found no significant differences between either the RS patients and the non-URS remaining patients or the treatment-resistant patients with no information about response to clozapine (data not shown).
In conclusion, this study is the first to report a positive association of rs3738401, a missense and potentially functional DISC1 variant with URS. Higher density SNP analysis of exon 2 of DISC1 and direct functional studies are warranted to better understand the functional role of rs3738401 and/or other DISC1 missense variants and their related haplotype in antipsychotic drug resistance.
